Terpos, E.; Zambello, R.; Leleu, X.; Kuehr, T.; Badelita, S.N.; Katodritou, E.; Brescianini, A.; Liang, T.; Wetten, S.; Caers, J.
Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe. Cancers 2022, 14, 5311.
https://doi.org/10.3390/cancers14215311
AMA Style
Terpos E, Zambello R, Leleu X, Kuehr T, Badelita SN, Katodritou E, Brescianini A, Liang T, Wetten S, Caers J.
Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe. Cancers. 2022; 14(21):5311.
https://doi.org/10.3390/cancers14215311
Chicago/Turabian Style
Terpos, Evangelos, Renato Zambello, Xavier Leleu, Thomas Kuehr, Sorina N. Badelita, Eirini Katodritou, Alessandra Brescianini, Tony Liang, Sally Wetten, and Jo Caers.
2022. "Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe" Cancers 14, no. 21: 5311.
https://doi.org/10.3390/cancers14215311
APA Style
Terpos, E., Zambello, R., Leleu, X., Kuehr, T., Badelita, S. N., Katodritou, E., Brescianini, A., Liang, T., Wetten, S., & Caers, J.
(2022). Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe. Cancers, 14(21), 5311.
https://doi.org/10.3390/cancers14215311